Curaleaf New Jersey Launches State’s First and Only Line of Strain Specific Pure Cannabis Vape Concentrate

NJ’s leading dispensary increases product offerings after receiving
state approval

BELLMAWR, N.J.–(BUSINESS WIRE)–Curaleaf New Jersey, a provider of state licensed cannabinoid-based
products, today launched a new line of natural, terpene rich, strain
specific, vaporable cannabis concentrates for patients of its Bellmawr
dispensary. The first in New Jersey to manufacture products in this
category, Curaleaf continues to set the industry standard by expanding
its already-diverse medical cannabis product offerings. This new product
line will help Curaleaf continue to provide quality care by offering a
delivery form that addresses specific patient needs.

The newly-launched product is available initially in four varieties,
Lavender, Strawberry Cough, Cookies and Canna-Tsu, all made with nothing
but NJ Department of Health approved pharmaceutical-grade cannabis
extract, strain specific cannabis and naturally derived terpenes. The
product comes in the form of vaporizer cartridges and will soon be
available in convenient disposable vape pens as well. Formulated by the
Curaleaf team, these products are developed at the company’s cultivation
and laboratory facility in Bellmawr using advanced extraction and
processing techniques for the purest oil and most robust strain
terpenes. The products are tested to ensure each cartridge has a
standardized amount of THC and or CBD for a consistent patient
experience.

“Receiving approval to launch these products is an important milestone
in the progression of Curaleaf’s operations as well as in New Jersey’s
medical cannabis program,” said George Schidlovsky, Curaleaf New
Jersey’s president. “As the largest dispensary on the East Coast,
serving hundreds of patients daily, Curaleaf has the resources and
production capacity to reliably market and distribute new products that
our patients depend on to live life well.”

“These concentrates, which surpass the state’s high standards of
quality, provide an alternative method of administration for patients
who may not be able to benefit from topical or oral forms of medical
cannabis,” said Schidlovsky. “Vaporizing cannabis concentrate is
considered a healthier alternative to smoking, and is a fast-acting form
of administration. I look forward to seeing the positive effect it has
on Curaleaf’s patients in New Jersey.”

Curaleaf complies with New Jersey state regulations and statutes that
regulate e-vaping. While the company serves pediatric patients with a
valid NJ Medical Marijuana card, it will not sell vaporizers to anyone
under the age of 21.

About Curaleaf

Curaleaf is a leading vertically integrated cannabis operator in the
United States. Headquartered in Wakefield, Massachusetts, Curaleaf has a
presence in 12 states, owns and operates 28 dispensaries, 12 cultivation
sites and nine processing sites with a focus on highly populated,
limited license states, including Florida, Massachusetts, New Jersey and
New York. Curaleaf leverages its extensive research and development
capabilities to distribute cannabis products in multiple formats with
the highest standard for safety, effectiveness, consistent quality and
customer care. Curaleaf is committed to being the industry’s leading
resource in education and advancement through research and advocacy.
More information regarding Curaleaf can be found at www.curaleaf.com.

Contacts

Curaleaf
Samantha Qualls, 212-889-0808
Curaleaf@marinopr.com